Precision medicine — using genomic, biomarker, and clinical data to tailor medical treatment to individual patient characteristics — is transitioning from research concept to commercial reality across oncology, rare disease, cardiology, and psychiatry. Pharmacogenomic testing — identifying how genetic variants affect drug metabolism and efficacy — is being integrated into PBM and clinical decision support platforms by CVS Caremark, OptumRx, and Cigna. Liquid biopsy — detecting cancer biomarkers from blood samples — is enabling earlier cancer detection and treatment monitoring. The commercial infrastructure for precision medicine at scale is being built by the major payers and PBMs as they integrate genomic data into coverage policies and care management programs.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Pharmacogenomics in PBM
• Liquid Biopsy Commercial Landscape
• Oncology Precision Medicine
• Rare Disease Genomics
• Payer Coverage of Genomic Tests
• Precision Medicine Data Infrastructure
• Regulatory Framework
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. Pharmacogenomics in PBM
4. Liquid Biopsy Commercial Landscape
5. Oncology Precision Medicine
6. Rare Disease Genomics
7. Payer Coverage of Genomic Tests
8. Precision Medicine Data Infrastructure
9. Regulatory Framework
10. Competitive Landscape
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. Pharmacogenomics in PBM
Table 3. Liquid Biopsy Commercial Landscape
Table 4. Oncology Precision Medicine
Table 5. Rare Disease Genomics
Table 6. Payer Coverage of Genomic Tests
Table 7. Precision Medicine Data Infrastructure
Table 8. Regulatory Framework
Table 9. Leading Companies — Technology Investment and Strategy 2025
Table 10. M&A and Partnership Activity 2023-2025
Table 11. Key Risks and Mitigation Strategies
Companies Profiled
Foundation Medicine
Guardant
Illumina
Myriad Genetics
Natera
Tempus
Thermo Fisher
